Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

398 - Thromboembolic events (TE) in patients with metastatic non small cell lung cancer (NSCLC) EGFR / ALK native treated with first-line platinum-based chemotherapy

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Victoria Eugenia Castellón Rubio

Citation

Annals of Oncology (2015) 26 (suppl_9): 111-124. 10.1093/annonc/mdv531

Authors

V.E. Castellón Rubio1, R. Luque Caro2, E. Gonzalez Flores2, L. Canosa Ruiz1

Author affiliations

  • 1 Medical Oncology, Hospital Torrecárdenas, 04009 - Almeria/ES
  • 2 Medical Oncology, Hospital Universitario Virgen de las Nieves, 18001 - Granada/ES
More

Resources

Abstract 398

Aim/Background

Venous thromboembolic disease is a common complication in cancer patients with a negative impact on their survival. In lung cancer, the scientific evidence for thrombosis during treatment with chemotherapy is limited. The objective of this study was to describe the incidence of thromboembolic events (TE) in patients with metastatic NSCLC, occurring during treatment with platinum-based chemotherapy, in the Torrecárdenas Hospital.

Methods

It's about a retrospective study of 100 patients with stage IV NSCLC (EGFR / ALK native) receiving first-line platinum-based chemotherapy. TE happening since the beginning of chemotherapy to 1.5 months after the last administration, are described.

Results

Median age was 59 years (37-78). 80% male. Most frequent histology: adenocarcinoma (70%) and degree of differentiation G3 (57%). Visceral metastatic disease (60%). 70 patients were treated with cisplatin-based and 30 patients received carboplatin regimen. 13 patients (13%) experienced a TE during treatment (8 episodes of pulmonary thromboembolism and 5 episodes of deep vein thrombosis). 13% (9/70) of TE in patients exposed to cisplatin vs 10% (4/30) in patients exposed to carboplatin. Most events occurred in the first 3 cycles (60%). The median PFS was similar in patients with and without TE (7.5 vs. 8.1 months). The median OS was lower in patients with TE (7.1 versus 11.7 months).

Conclusions

In our study, the incidence of TE in patients with metastatic NSCLC is higher than that described in previous studies. TE most occur in the first three cycles, and their appearance is associated with increased mortality. Adenocarcinoma, degree of differentiation 3, visceral metastases and chemotherapy based on platinum, are risk factors for TE in stage IV NSCLC.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings